Ken Griffin Immunovant, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $1.09 Million - $1.09 Million	39,500 Added 66.72%	98,700 $2.72 Million
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $888,540 - $1.12 Million	35,400 Added 148.74%	59,200 $1.56 Million
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $33,297 - $48,169	-1,100 Reduced 4.42%	23,800 $768,000
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $3.23 Million - $4.56 Million	-103,300 Reduced 80.58%	24,900 $1.05 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $2.15 Million - $4.64 Million	116,000 Added 950.82%	128,200 $4.92 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $12,780 - $21,375	900 Added 7.96%	12,200 $231,000
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $152,700 - $197,200	10,000 Added 769.23%	11,300 $175,000
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $8,567 - $23,075	1,300 New	1,300 $23,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.